Comparative analysis of endometrium after using levonorgestrel-releasing intrauterine system and copper intrauterine device

Abstract

BACKGROUND: To date, the risks of pelvic inflammatory diseases, including chronic endometritis, associated with the use of various intrauterine contraceptives, have remained debatable.

AIM: The aim of this study was to conduct a comparative analysis of the endometrial status in women of reproductive age after the use of copper- or levonorgestrel-releasing intrauterine device.

MATERIALS AND METHODS: Morphological and immunohistochemical studies of endometrial biopsies obtained by aspiration Pipelle biopsy were performed after intrauterine device extraction in 18 patients who used a copper-containing intrauterine device and in 12 women who used the levonorgestrel-releasing intrauterine device Mirena. Monoclonal mouse antibodies to CD20, CD138, and α-smooth muscle actin (DAKO, Denmark) were used. Criteria for inclusion of patients in the study are reproductive age, use of an intrauterine device for five years, absence of complications associated with the intrauterine device during its use. Exclusion criteria are a history of pelvic inflammatory diseases, sexually transmitted infections, habitual miscarriage, two or more intrauterine interventions.

RESULTS: After using a copper-containing intrauterine device, signs of chronic inflammation were found in the endometrium such as cytogenic stroma fibrosis with pronounced infiltration by inflammatory cells, positive expression of CD138 (33.3% of observations), CD20 (88.9% of observations with an average number of 27.4 ± 5.7), α-smooth muscle actin (up to 70% of the cytogenic stroma area), and the presence of lymphatic follicles consisting of B lymphocytes (33.3% of observations). During the use of the levonorgestrel-releasing intrauterine device, decidual transformation of cytogenic stroma cells, as well as secretion and atrophy of the glandular epithelium, were found in the endometrium. CD20-positive cells were detected in five out of 12 cases (41.6% of observations with an average number of 12.8 ± 4.6). Expression of CD138 and α-smooth muscle actin was not detected in any of the cases.

CONCLUSIONS: The use of a copper-containing intrauterine device is associated with a high risk of developing chronic endometritis. The absence of signs of chronic inflammation in the endometrium after the use of a levonorgestrel-releasing intrauterine device is probably due to the protective effect of levonorgestrel on the uterine mucosa. Thus, levonorgestrel-releasing intrauterine devices, in comparison with copper-containing intrauterine devices, have a favorable safety profile relative to the endometrium and can be recommended for women of reproductive age, including those who have not given birth.

Keywords

intrauterine contraception / levonorgestrel-releasing intrauterine device / Mirena / copper-containing intrauterine device / endometrium / chronic endometritis

References

[1] Scott JR, Gibbs RS, Karlan BY, et al, editors. Danforth’s obstetrics and gynecology. New York: Lippincott Williams and Wilkins; 2003.

[2] Scott J.R., Gibbs R.S., Karlan B.Y., editors. Danforth’s obstetrics and gynecology. New York: Lippincott Williams and Wilkins, 2003.

[3] Prilepskaya VN, editor. Guide to contraception. Moscow: MEDpress-inform; 2006. EDN: QLMKOB

[4] Руководство по контрацепции / под ред. В.Н. Прилепской. Москва: МЕДпресс-информ, 2006. EDN: QLMKOB

[5] Uvarova EV. Hormonal contraception: what is it, what is it like, why and who needs it, how to use it? Effective pharmacotherapy. 2011;(1):14–24. (In Russ.) EDN: SELCCH

[6] Уварова Е.В. Гормональная контрацепция: что это такое, какой она бывает, зачем и кому она нужна, как ее применять? // Эффективная фармакотерапия. 2011. № 1. С. 14–24. EDN: SELCCH

[7] Federal State Budgetary Institution National Medical Research Center of Obstetrics, Gynecology and Perinatology named after. Academician V.I. Kulakov Ministry of Health of the Russian Federation, Russian Society of Obstetricians and Gynecologists, Russian Society for Contraception. National medical criteria for the acceptability of contraceptive methods. Adapted document “Medical eligibility criteria for the use of WHO contraceptive methods, 5th edition, 2015”. Sukhikh GT, Prilepskaya VN, editors. Moscow; 2023 [cited 18.08.2023]. (In Russ.) Available from: https://drive.google.com/file/d/1eO4kz5jjSNxJzHvAklVN3CdPwOW8ZH10/view

[8] ФГБУ НМИЦ акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Министерства Здравоохранения РФ, Российское общество акушеров-гинекологов, Российское общество по контрацепцииНациональные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5 издание, 2015» / под ред. Г.Т. Сухих, В.Н. Прилепской. Москва, 2023. Режим доступа: https://drive.google.com/file/d/1eO4kz5jjSNxJzHvAklVN3CdPwOW8ZH10/view. Дата обращения: 18.08.2023.

[9] Bitzer J. Contraceptive compliance — why is contraceptive failure still so frequent? Ther Umsch. 2009;66(2):137–143. doi: 10.1024/0040-5930.66.2.137

[10] Bitzer J. Contraceptive compliance — why is contraceptive failure still so frequent? //Ther Umsch. 2009. Vol. 66, N. 2. P. 137–143. doi: 10.1024/0040-5930.66.2.137

[11] ACOG Practice Bulletin N. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol. 2011;118(1):184–196. doi: 10.1097/AOG.0b013e318227f05e

[12] ACOG Practice Bulletin N. 121: long-acting reversible contraception: implants and intrauterine devices // Obstet Gynecol. 2011. Vol. 118, N. 1. P. 184–196. doi: 10.1097/AOG.0b013e318227f05e

[13] Hatcer RA, Trussell J, Stewart F, et al. Contraceptive technology. New York: Ardent Media;2007.

[14] Hatcher R.A., Trussell J., Stewart F., et. al. Contraceptive technology. New York, NY. Ardent Media, 2007.

[15] Prilepskaya VN, Tarasova MA, Nazarova NM, et al. International project “CHOICE”: a brief overview of the research results. Gynecology. 2010;12(4):26–28. (In Russ.) EDN: NBJVNR

[16] Прилепская В.Н., Назарова Н.М., Тарасова М.А., и др. Международный проект «CHOICE»: краткий обзор результатов исследования // Гинекология. 2010. Т. 12, № 4. С. 26–28. EDN: NBJVNR

[17] Thompson KM, Speidel JJ, Saporta V, et al. Contraceptive policies affect post-abortion provision of longacting reversible contraception. Contraception. 2011;83(1):41–47. doi: 10.1016/j.contraception.2010.06.008

[18] Thompson K.M., Speidel J.J., Saporta V., et al. Contraceptive policies affect post-abortion provision of longacting reversible contraception // Contraception. 2011. Vol. 83, N. 1. P. 41–47. doi: 10.1016/j.contraception.2010.06.008

[19] Manuilova IA. Modern contraceptives. Moscow: Medicine; 1983. (In Russ.)

[20] Мануилова И.А. Современные контрацептивные средства. Москва: Медицина, 1983.

[21] Berek JS, editor. Novak’s Gynecology. Lippincott Williams and Wilkins; 2002. (In Russ.)

[22] Гинекология по Эмилю Новаку / под ред. Дж. Берека, И. Адаши, П. Хиллард. Москва: Практика, 2002.

[23] Speroff L, Darney FD. Clinical guidelines for contraception. Moscow: BINOM; 2009. EDN: QLTGOX

[24] Сперофф Л., Дарни Ф.Д. Клиническое руководство по контрацепции. Москва: БИНОМ, 2009. EDN: QLTGOX

[25] French RS, Cowan FM, Mansour D, et al. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. BJOG. 2000;107(10):1218–1225. doi: 10.1111/j.1471-0528.2000.tb11610.x

[26] French R.S., Cowan F.M., Mansour D., et al. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives // BJOG. 2000. Vol. 107, N. 10. P. 1218–1225. doi: 10.1111/j.1471-0528.2000.tb11610.x

[27] Novikov YuI, Kononova ES. The effectiveness of intrauterine contraceptives, side effects and complications during their use // Obstetrics and Gynecology. 1999;(7):46–48. (In Russ.) EDN: OEYVTH

[28] Комарова В.С., Хлыбова С.В., Зайцева Е.Течение воспалительных заболеваний органов малого таза на фоне длительного применения внутриматочных контрацептивов // Вятский медицинский вестник. 2010. № 3. С. 8–14. EDN: OEYVTH

[29] Petrov YuA. Family and health. Moscow: Medical Book; 2014. (In Russ.) EDN: VRRMTD

[30] Новиков Ю.И., Кононова Е.С. Эффективность внутриматочных контрацептивов, побочные явления и осложнения при их применении // Акушерство и гинекология. 1999. № 7. С. 46–48.

[31] Petrov YuA, Radzinsky VE, Kalinina EA, et al. Possibilities of targeted therapy for chronic endometritis taking into account the pathomorphotype. Medical Bulletin of the South of Russia. 2015;(4):71–75. (In Russ.)

[32] Петров Ю.А. Семья и здоровье. Москва: Медицинская книга, 2014. EDN: VRRMTD

[33] Petrov YuA. Chronic endometritis in reproductive age: etiology, pathogenesis, diagnosis, treatment and prevention [dissertation]. Moscow; 2012. (In Russ.) EDN: QFNNXJ

[34] Петров Ю.А., Радзинский В.Е., Калинина Е.А., и др. Возможности таргентной терапии хронического эндометрита с учетом патоморфотипа // Медицинский вестник Юга России. 2015. № 4. С. 71–75.

[35] Protasova IN, Tskhai VB, Peryanova OV, et al. Clinical, immunological and microbiological indicators for purulent inflammatory diseases of the uterine appendages that developed during the use of intrauterine contraception. Bulletin of the Novosibirsk State University. Series: biology, clinical medicine. 2007;(1):10–14. EDN: HYHUXN (In Russ.)

[36] Петров Ю.А. Хронический эндометрит в репродуктивном возрасте: этиология, патогенез, диагностика, лечение и профилактика: дис. ... доктора мед. наук. Москва, 2012. EDN: QFNNXJ

[37] Strukova VA. Correction of dysbiosis of the reproductive tract in women after long-term use of intrauterine contraceptives. Bulletin of the Orenburg State University. 2012;(6):22–25. (In Russ.) EDN: PDQVTP

[38] Протасова И.Н., Цхай В.Б., Перьянова О.В., и др. Клинико-иммунологические и микробиологические показатели при гнойных воспалительных заболеваниях придатков матки, развившихся при использовании внутриматочной контрацепции // Вестник Новосибирского государственного университета. Серия: биология, клиническая медицина. 2007. № 1. С. 10–14. EDN: HYHUXN

[39] Surico N, Tavassoli K, Porcelli A, et al. Risk of occurrence of pelvic inflammatory disease correlated with the duration of use of an intrauterine device. Minerva Ginecol. 1985;37(3):105–108.

[40] Струкова В.А. Коррекция дисбиоза половых путей у женщин после длительного применения внутриматочных контрацептивов // Вестник Оренбургского государственного университета. 2012. № 6(142). С. 22–25. EDN: PDQVTP

[41] Sufrin CB, Postlethwaite D, Armstrong MA, et al. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol. 2012;120(6):1314–1321. doi: 10.1097/aog.0b013e318273364c

[42] Surico N., Tavassoli K., Porcelli A., et al. Risk of occurrence of pelvic inflammatory disease correlated with the duration of use of an intrauterine device // Minerva Ginecol. 1985. Vol. 37, N. 3. P. 105–108.

[43] Birgisson NE, Zhao Q., Secura GM, et al. Positive testing for neisseria gonorrhoeae and chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users. J Womens Health. 2015;24(5):354–359. doi: 10.1089/jwh.2015.5190

[44] Sufrin C.B., Postlethwaite D., Armstrong M.A. et al. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease // Obstet Gynecol. 2012. Vol. 120, N. 6. P. 1314–1321. doi: 10.1097/aog.0b013e318273364c

[45] Gemzell-Danielsson K, Apter D, Hauck B, et al. The effect of age, parity and body mass index on the efficacy, safety, placement and user satisfaction associated with two low-dose levonorgestrel intrauterine contraceptive systems: subgroup analyses of data from a phase III trial. PLoS One. 2015;10(9). doi: 10.1371/journal.pone.0135309

[46] Birgisson N.E., Zhao Q., Secura G.M., et al. Positive testing for neisseria gonorrhoeae and chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users // J Womens Health. 2015. Vol. 24, N. 5. P. 354–359. doi: 10.1089/jwh.2015.5190

[47] Turok DK, Eisenberg DL, Teal SB, et al. A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement. Am J Obstet Gynecol. 2016;215(5):599.e1–599.e6. doi: 10.1016/j.ajog.2016.05.017

[48] Gemzell-Danielsson K., Apter D., Hauck B., et al. The effect of age, parity and body mass index on the efficacy, safety, placement and user satisfaction associated with two low-dose levonorgestrel intrauterine contraceptive systems: subgroup analyses of data from a phase III trial // PLoS One. 2015. Vol. 10, N. 9. doi: 10.1371/journal.pone.0135309

[49] Gemzell-Danielsson K, Apter D, Dermout S, et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. Eur J Obstet Gynecol Reprod Biol. 2017;210:22–28. doi: 10.1016/j.ejogrb.2016.11.022

[50] Turok D.K., Eisenberg D.L., Teal S.B., et al. A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placementet // Am J Obstet Gynecol. 2016. Vol. 215, N. 5. P. 599.e1–599.e6. doi: 10.1016/j.ajog.2016.05.017

[51] Feichter GE, Tauber PF, Rosenthal E, Ludwig H. Zur bakteriellen Besiedlung kupferhaltiger Intrauterinpessare. Geburtshilfe Frauenheilkd. 1978;38(11):904–914. (In Germ.)

[52] Gemzell-Danielsson K., Apter D., Dermout S., et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use // Eur J Obstet Gynecol Reprod Biol. 2017. Vol. 210. P. 22–28. doi: 10.1016/j.ejogrb.2016.11.022

[53] Alipov VI, Korkhov VV. Contraceptives. Leningrad: Medicine; 1985. (In Russ.)

[54] Feichter G.E., Tauber P.F., Rosenthal E., et al. Zur bakteriellen Besiedlung kupferhaltiger Intrauterinpessare // Geburtshilfe Frauenheilkd. 1978. Vol. 38, N. 11. P. 904–914.

[55] Arndt IG, Petrov YuA. Clinical aspects of the use of subcutaneous hormonal contraceptives. Tauride medical and biological bulletin. 2016;19(2):15–17. (In Russ.) EDN: WCEXNZV

[56] Алипов В.И., Корхов В.В. Противозачаточные средства. Ленинград: Медицина, 1985.

[57] World Health Organization. Intrauterine devices and their role in family planning. Geneva; 1995. (In Russ.) EDN: WCEXNZ

[58] Арндт И.Г., Петров Ю.А. Клинические аспекты применения подкожных гормональных контрацептивов // Таврический медико-биологический вестник. 2016. Т. 19, № 2. С. 15–17. EDN: WCEXNZ

[59] Apter D, Gemzell-Danielsson K, Hauck B, et al. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014;101(6). doi: 10.1016/j.fertnstert.2014.03.004

[60] Всемирная Организация Здравоохранения. Внутриматочные средства и их роль в планировании семьи. Женева, 1995.

[61] Sukhikh GT, Shurshalina AV. Chronic endometritis: a guide. Moscow: Geotar-Media; 2013. (In Russ.) EDN: GCLHKW

[62] Apter D., Gemzell-Danielsson K., Hauck B., et al. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies // Fertil Steril. 2014. Vol. 101, N. 6. P. 1656–1662. doi: 10.1016/j.fertnstert.2014.03.004

[63] Ellinidi VN, Feoktistov AA, Kazantsev VA, et al. Prognostic value of two morphological forms of chronic endometritis: polypoid and follicular one. Russian Journal of Human Reproduction. 2020;26(1):55-58. (In Russ.) EDN: BZQOAG doi: 10.17116/repro20202601155

[64] Сухих Г.Т., Шуршалина А.В. Хронический эндометрит: руководство. Москва: Геотар-Медиа, 2013. EDN: GCLHKW

[65] Эллиниди В.Н., Феоктистов А.А., Казанцева В.А., и др. Прогностическое значение двух клинико-морфологических форм хронического эндометрита — полиповидного и фолликулярного при экстракорпоральном оплодотворении // Проблемы репродукции. 2020. Т. 26, № 1. С. 55–58. EDN: BZQOAG doi: 10.17116/repro20202601155

RIGHTS & PERMISSIONS

Eсо-Vector